PA
BCAX

Profund Advisors’s Bicara Therapeutics BCAX Stock Holding History

Profund Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Sell
17,128
-5,049
-23% -$86.9K 0.01% 680
2025
Q4 		$373K Buy
+22,177
New +$379K 0.01% 729

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Profund Advisors's BCAX Position: Q1 2026 in Review

Profund Advisors reduced its Bicara Therapeutics (BCAX) stake by 23% in Q1 2026, selling an estimated $86.9K and leaving 17,128 shares worth $341K. The position accounts for 0.01% of the portfolio, ranked #680.

Profund Advisors first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. The position peaked at $373K in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Profund Advisors held 17,128 shares of Bicara Therapeutics worth $341K as of Q1 2026.
  • Profund Advisors sold 5,049 Bicara Therapeutics shares in Q1 2026, an estimated $86.9K.
  • Bicara Therapeutics made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #680 holding.
  • Profund Advisors first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Profund Advisors's Bicara Therapeutics position peaked at $373K in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.